Benjamin E Peterson1, Deepak L Bhatt2. 1. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. 2. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. dlbhattmd@post.harvard.edu.
Abstract
PURPOSE OF REVIEW: This review aims to discuss the use of antithrombotic therapy in patients with atrial fibrillation who undergo coronary stenting with emphasis on the use of double vs triple therapy. RECENT FINDINGS: When combined with systemic anticoagulation, dual antiplatelet therapy results in an unacceptable increase in bleeding without any improvement in prevention of thrombotic events. Direct oral anticoagulants combined with single antiplatelet therapy have reduced bleeding compared with warfarin plus dual antiplatelet therapy. Triple anticoagulation therapy with warfarin or direct oral anticoagulants leads to an excess of bleeding and is not superior in preventing thrombotic events. Recent randomized, controlled trials have shown a significant reduction in major bleeding events in patients treated with dual antithrombotic therapy compared with triple therapy without any difference in efficacy. These findings call into question whether triple therapy should remain a part of standard practice.
PURPOSE OF REVIEW: This review aims to discuss the use of antithrombotic therapy in patients with atrial fibrillation who undergo coronary stenting with emphasis on the use of double vs triple therapy. RECENT FINDINGS: When combined with systemic anticoagulation, dual antiplatelet therapy results in an unacceptable increase in bleeding without any improvement in prevention of thrombotic events. Direct oral anticoagulants combined with single antiplatelet therapy have reduced bleeding compared with warfarin plus dual antiplatelet therapy. Triple anticoagulation therapy with warfarin or direct oral anticoagulants leads to an excess of bleeding and is not superior in preventing thrombotic events. Recent randomized, controlled trials have shown a significant reduction in major bleeding events in patients treated with dual antithrombotic therapy compared with triple therapy without any difference in efficacy. These findings call into question whether triple therapy should remain a part of standard practice.
Authors: Manan Pareek; Deepak L Bhatt; Jürrien M Ten Berg; Steen D Kristensen; Erik L Grove Journal: Expert Opin Pharmacother Date: 2017-05-22 Impact factor: 3.889
Authors: Dragos Vinereanu; Susanna R Stevens; John H Alexander; Sana M Al-Khatib; Alvaro Avezum; Marıa Cecilia Bahit; Christopher B Granger; Renato D Lopes; Sigrun Halvorsen; Michael Hanna; Steen Husted; Elaine M Hylek; Andrei D Mărgulescu; Lars Wallentin; Dan Atar Journal: Eur Heart J Date: 2015-09-14 Impact factor: 29.983
Authors: Christian T Ruff; Deepak L Bhatt; Ph Gabriel Steg; Bernard J Gersh; Mark J Alberts; Elaine B Hoffman; E Magnus Ohman; Kim A Eagle; Gregory Y H Lip; Shinya Goto Journal: Int J Cardiol Date: 2013-11-25 Impact factor: 4.164
Authors: Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther Journal: N Engl J Med Date: 2016-08-30 Impact factor: 91.245
Authors: Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray Journal: Circulation Date: 2013-12-17 Impact factor: 29.690
Authors: Harsh B Golwala; Christopher P Cannon; Ph Gabriel Steg; Gheorghe Doros; Arman Qamar; Stephen G Ellis; Jonas Oldgren; Jurrien M Ten Berg; Takeshi Kimura; Stefan H Hohnloser; Gregory Y H Lip; Deepak L Bhatt Journal: Eur Heart J Date: 2018-05-14 Impact factor: 35.855
Authors: Jonas Oldgren; Lars Wallentin; John H Alexander; Stefan James; Birgitta Jönelid; Gabriel Steg; Johan Sundström Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983